{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T20:10:15Z","timestamp":1789157415056,"version":"build-2803163510"},"reference-count":27,"publisher":"ALUNA","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,31]]},"abstract":"<jats:p>Aim: Progression of type 2 diabetes produces capillary and macrovascular problems, including microalbuminuria, an early renal impairment marker. This study examines biochemical factors associated to microalbuminuria in T2DM patients of varying durations.\nMaterials and Methods: The study included 90 healthy controls, patients with type 2 diabetes mellitus (T2DM) for less than five years, and those with the illness for more than five years. Fasting blood glucose, HbA1c, lipid profile (HDL, LDL, vLDL, TC), serum albumin, globulins, creatinine, and urine microalbumin were tested. To compare groups, ANOVA and independent t-tests were utilized.\nResults: Patients with long-term illness showed higher fasting glucose (210.17\u00b15.98 mg\/dL), HbA1c (8.94\u00b10.51%), serum creatinine (122.01\u00b10.28 \u03bcmol\/L), and reduced albumin (33.42\u00b13.61 g\/L Diabetics often had greater LDL, vLDL, and TC levels than controls (p&lt;0.001). Microalbuminuria is connected to renal and metabolic dysfunction.\nConclusions: These findings suggest biochemical markers and microalbuminuria may predict T2DM. Early detection of these indications may help doctors prevent chronic kidney disease and cardiovascular issues.<\/jats:p>","DOI":"10.36740\/merkur202604101","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:35:43Z","timestamp":1789155343000},"page":"404","source":"Crossref","is-referenced-by-count":0,"title":["Determinants of biochemical factors and microalbuminuria among type 2 diabetes mellitus patients"],"prefix":"10.36740","volume":"54","author":[{"given":"Ruqaya M.","family":"Hassan","sequence":"first","affiliation":[{"name":"DEPARTMENT OF BIOTECHNOLOGY, COLLEGE OF SCIENCE, UNIVERSITY OF BAGHDAD, BAGHDAD, IRAQ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mawj N.","family":"Modher","sequence":"additional","affiliation":[{"name":"BIOTECHNOLOGY RESEARCH CENTER, AL-NAHRAIN UNIVERSITY, BAGHDAD, IRAQ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahad M.","family":"Hussain","sequence":"additional","affiliation":[{"name":"MEDICAL PHYSICS DEPARTMENT, COLLEGE OF SCIENCE, AL-NAHRAIN UNIVERSITY, BAGHDAD, IRAQ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baneen S.","family":"Rasool","sequence":"additional","affiliation":[{"name":"CHEMISTRY DEPARTMENT, COLLEGE OF SCIENCE, AL-NAHRAIN UNIVERSITY, BAGHDAD, IRAQ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousif Sh.","family":"Raheem","sequence":"additional","affiliation":[{"name":"DEPARTMENT OF BIOLOGY, COLLEGE OF SCIENCE, UNIVERSITY OF BAGHDAD, BAGHDAD, IRAQ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Flayyih","family":"Hasan","sequence":"additional","affiliation":[{"name":"BIOTECHNOLOGY RESEARCH CENTER, AL-NAHRAIN UNIVERSITY, BAGHDAD, IRAQ; DEPARTMENT OF MEDICAL LABORATORY TECHNIQUES, COLLEGE OF HEALTH AND MEDICAL TECHNOLOGY, AL- FARABI UNIVERSITY, BAGHDAD, IRAQ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22436","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1. Mahgoub MO, Ali II, Adeghate JO, Tekes K, Kalasz H, Adeghate EA. An update on the molecular and cellular basis of pharmacotherapy in type 2 diabetes mellitus. Int J Mol Sci. 2023;24(11):9328. doi.org\/10.3390\/ijms24119328.","DOI":"10.3390\/ijms24119328"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2. Kasar KAK. Evaluation of Changes in Levels of Serum Selenium in Diabetic Pateints and in Diabetic Pateints with Cardiovascular Disease. Al-Nahrain J Sci. 2011;14(2):58-66. doi: 10.22401\/JNUS.14.2.07.","DOI":"10.22401\/JNUS.14.2.07"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3. Kulkarni A, Thool AR, Daigavane S. Understanding the clinical relationship between diabetic retinopathy, nephropathy, and neuropathy: a comprehensive review. Cureus. 2024;16(3). doi: 10.7759\/cureus.56674.","DOI":"10.7759\/cureus.56674"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4. Beernink JM, van Mil D, Laverman GD, Heerspink HJ, Gansevoort RT. Developments in albuminuria testing: A key biomarker for detection, prognosis and surveillance of kidney and cardiovascular disease - A practical update for clinicians. Diabetes Obes Metab. 2025. doi: 10.1111\/dom.16359.","DOI":"10.1111\/dom.16359"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5. Hussein Z, Al-Qaisi J. Effect of diabetes mellitus type 2 on pituitary gland hormones (FSH, LH) in men and women in Iraq. Al-Nahrain J Sci. 2012;15(3):75-9. doi: 10.22401\/JNUS.15.3.11.","DOI":"10.22401\/JNUS.15.3.11"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6. Sarkar S, Elliott EC, Henry HR, Ludovico ID, Melchior JT, Frazer-Abel A, et al. Systematic review of type 1 diabetes biomarkers reveals regulation in circulating proteins related to complement, lipid metabolism, and immune response. Clin Proteomics. 2023;20(1):38. doi: 10.1186\/s12014-023-09429-6.","DOI":"10.1186\/s12014-023-09429-6"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7. Mengstie MA, Chekol Abebe E, Behaile Teklemariam A, Tilahun Mulu A, Agidew MM, Teshome Azezew M, et al. Endogenous advanced glycation end products in the pathogenesis of chronic diabetic complications. Front Mol Biosci. 2022;9:1002710.","DOI":"10.3389\/fmolb.2022.1002710"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8. Wang N, Zhang C. Recent advances in the management of diabetic kidney disease: slowing progression. Int J Mol Sci. 2024;25(6):3086. doi: 10.3389\/fmolb.2022.1002710.","DOI":"10.3390\/ijms25063086"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9. Abdelwahid HA, Dahlan HM, Mojemamy GM, Darraj GH. Predictors of microalbuminuria and its relationship with glycemic control among Type 2 diabetic patients of Jazan Armed Forces Hospital, southwestern Saudi Arabia. BMC Endocr Disord.. 2022;22(1):307. doi: 10.1186\/s12902-022-01232-y.","DOI":"10.1186\/s12902-022-01232-y"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10. Zhang Y-Y, Gui J, Chen B-X, Wan Q. Correlation of renal function indicators and vascular damage in T2DM patients with normal renal function. Front Endocrinol. 2023;14:1292397. doi: 10.3389\/fendo.2023.1292397.","DOI":"10.3389\/fendo.2023.1292397"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11. Ali A, Hamzah MI, Khudhair MS. The Role of Serum Angiopoietin-Like Protein 4 (ANGPTL-4) and its Gene in Iraq Patients with Type2 Diabetes Mellitus: Case-Control Study. Al-Nahrain J Sci. 2021;24(4):7-14.","DOI":"10.22401\/ANJS.24.4.02"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12. Lamsal L, Joshi R, Bhattarai M, Parajuli B, Timilsina S, Kunwor B, et al. Prevalence and clinical correlates of microalbuminuria among patients of essential hypertension in tertiary care center of Nepal: A cross-sectional study. Medicine. 2025;104(26):e43075. doi: 10.1097\/MD.0000000000043075.","DOI":"10.1097\/MD.0000000000043075"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13. Claudel SE, Verma A. Albuminuria in cardiovascular, kidney, and metabolic disorders: a state-of-the-art review. Circulation. 2025;151(10):716-32. doi: 10.1161\/CIRCULATIONAHA.124.071079.","DOI":"10.1161\/CIRCULATIONAHA.124.071079"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14. Chadha GS, Morris ME. An extended minimal physiologically based pharmacokinetic model: evaluation of type II diabetes mellitus and diabetic nephropathy on human IgG pharmacokinetics in rats. AAPS J. 2015;17(6):1464-74. doi: 10.1208\/s12248-015-9810-0.","DOI":"10.1208\/s12248-015-9810-0"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15. Hirano T. Pathophysiology of diabetic dyslipidemia. Journal of atherosclerosis and thrombosis. 2018;25(9):771-82. doi; 10.5551\/jat.RV17023.","DOI":"10.5551\/jat.RV17023"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16. Huhtala M, Ronnemaa T, Tertti K. Insulin resistance is associated with an unfavorable serum lipoprotein lipid profile in women with newly diagnosed gestational diabetes. Biomolecules. 2023;13(3):470. doi: 10.3390\/biom13030470.","DOI":"10.3390\/biom13030470"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2009 Mar;5(3):150-9. doi: 10.1038\/ncpendmet1066.","DOI":"10.1038\/ncpendmet1066"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18. Rivetti G, Hursh BE, Miraglia del Giudice E, Marzuillo P. Acute and chronic kidney complications in children with type 1 diabetes mellitus. Pediatr Nephrol. 2023 May;38(5):1449-1458. doi: 10.1007\/s00467-022-05689-w.","DOI":"10.1007\/s00467-022-05689-w"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19. Jung C-Y, Yoo T-H. Pathophysiologic mechanisms and potential biomarkers in diabetic kidney disease. Diabetes Metab J. 2022 Mar;46(2):181-197. doi: 10.4093\/dmj.2021.0329.","DOI":"10.4093\/dmj.2021.0329"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"20. Qiu J, Yard BA, Kramer BK, van Goor H, van Dijk P, Kannt A. Association between serum carnosinase concentration and activity and renal function impairment in a type-2 diabetes cohort. Front Pharmacol. 2022;13:899057. doi:10.3389\/fphar.2022.899057.","DOI":"10.3389\/fphar.2022.899057"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21. Le P, Ayers G, Misra-Hebert AD, Herzig SJ, Herman WH, Shaker VA, et al. Adherence to the American Diabetes Association\u2019s glycemic goals in the treatment of diabetes among older Americans, 2001\u20132018. Diabetes Care. 2022;45(5):1107-15. doi: 10.2337\/dc21-1507.","DOI":"10.2337\/dc21-1507"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"22. Hasan M, Fariha KA, Barman Z, Mou AD, Miah R, Habib A, et al. Assessment of the relationship between serum xanthine oxidase levels and type 2 diabetes: A cross-sectional study. Sci Rep. 2022;12(1):20816. doi: 10.1038\/s41598-022-25413-w","DOI":"10.1038\/s41598-022-25413-w"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"23. Yang K-J, Park H, Chang Y-K, Park CW, Kim SY, Hong YA. Xanthine oxidoreductase inhibition ameliorates high glucose-induced glomerular endothelial injury by activating AMPK through the purine salvage pathway. Sci Rep. 2024;14(1):11167. doi: 10.1038\/s41598-024-61436-1.","DOI":"10.1038\/s41598-024-61436-1"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"24. Mostafa M, Morsy EY, Maklad H, Elrahmany SM, Mohamed Haji SA. Serum calprotectin in patients with type 2 diabetes mellitus and its relation to microvascular complications. ALEXMED ePosters. 2024;6(2):13-4. doi: 10.21608\/alexpo.2024.287807.1833.","DOI":"10.21608\/alexpo.2024.287807.1833"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"25. Garcia V, Perera YR, Chazin WJ. A structural perspective on calprotectin as a ligand of receptors mediating inflammation and potential drug target. Biomolecules. 2022;12(4):519. doi: 10.3390\/biom12040519.","DOI":"10.3390\/biom12040519"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"26. Oosterwijk MM, Bakker SJ, Nilsen T, Navis G, Laverman GD. Determinants of increased serum calprotectin in patients with type 2 diabetes mellitus. Int J Mol Sci. 2020 Oct 29;21(21):8075. doi: 10.3390\/ijms21218075.","DOI":"10.3390\/ijms21218075"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"27. Mandrekar JN. Simple statistical measures for diagnostic accuracy assessment. J Thorac Oncol. 2010;5(6):763-4. doi: 10.1097\/JTO.0b013e3181dab122.","DOI":"10.1097\/JTO.0b013e3181dab122"}],"container-title":["Polski Merkuriusz Lekarski"],"original-title":[],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:35:51Z","timestamp":1789155351000},"score":1,"resource":{"primary":{"URL":"https:\/\/polskimerkuriuszlekarski.pl\/wp-content\/uploads\/library\/PolMerkurLek2026i4net.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8,31]]},"published-print":{"date-parts":[[2026,8,31]]}},"URL":"https:\/\/doi.org\/10.36740\/merkur202604101","relation":{},"ISSN":["1426-9686"],"issn-type":[{"value":"1426-9686","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,31]]}}}